Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy

Stefan E. Eng, Benjamin Basasie, Alfonso Lam, O. John Semmes, Dean A. Troyer, Geoffrey D. Clarke, Abhijit G. Sunnapwar, Robin J. Leach, Teresa L. Johnson-Pais, Lori J. Sokoll, Daniel W. Chan, Jeffrey J. Tosoian, Javed Siddiqui, Arul M. Chinnaiyan, Ian M. Thompson, Paul C. Boutros, Michael A Liss

Resultado de la investigación: Articlerevisión exhaustiva


Background: Protocol-based active surveillance (AS) biopsies have led to poor compliance. To move to risk-based protocols, more accurate imaging biomarkers are needed to predict upgrading on AS prostate biopsy. We compared restriction spectrum imaging (RSI-MRI) generated signal maps as a biomarker to other available non-invasive biomarkers to predict upgrading or reclassification on an AS biopsy. Methods: We prospectively enrolled men on prostate cancer AS undergoing repeat biopsy from January 2016 to June 2019 to obtain an MRI and biomarkers to predict upgrading. Subjects underwent a prostate multiparametric MRI and a short duration, diffusion-weighted enhanced MRI called RSI to generate a restricted signal map along with evaluation of 30 biomarkers (14 clinico-epidemiologic features, 9 molecular biomarkers, and 7 radiologic-associated features). Our primary outcome was upgrading or reclassification on subsequent AS prostate biopsy. Statistical analysis included operating characteristic improvement using AUROC and AUPRC. Results: The individual biomarker with the highest area under the receiver operator characteristic curve (AUC) was RSI-MRI (AUC = 0.84; 95% CI: 0.71–0.96). The best non-imaging biomarker was prostate volume-corrected Prostate Health Index density (PHI, AUC = 0.68; 95% CI: 0.53–0.82). Non-imaging biomarkers had a negligible effect on predicting upgrading at the next biopsy but did improve predictions of overall time to progression in AS. Conclusions: RSI-MRI, PIRADS, and PHI could improve the predictive ability to detect upgrading in AS. The strongest predictor of clinically significant prostate cancer on AS biopsy was RSI-MRI signal output.

Idioma originalEnglish (US)
PublicaciónProstate Cancer and Prostatic Diseases
EstadoAccepted/In press - 2022

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research


Profundice en los temas de investigación de 'Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy'. En conjunto forman una huella única.

Citar esto